0000950170-23-053381.txt : 20231013
0000950170-23-053381.hdr.sgml : 20231013
20231013201841
ACCESSION NUMBER: 0000950170-23-053381
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231011
FILED AS OF DATE: 20231013
DATE AS OF CHANGE: 20231013
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Buell Jennifer
CENTRAL INDEX KEY: 0001711184
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40908
FILM NUMBER: 231326060
BUSINESS ADDRESS:
BUSINESS PHONE: 781-674-4400
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MiNK Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 212-994-8250
MAIL ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: AgenTus Therapeutics, Inc.
DATE OF NAME CHANGE: 20210112
4
1
ownership.xml
4
X0508
4
2023-10-11
0001840229
MiNK Therapeutics, Inc.
INKT
0001711184
Buell Jennifer
149 FIFTH AVENUE, SUITE 500
NEW YORK
NY
10010
true
true
false
false
Chief Executive Officer
false
Common Stock
2023-10-11
4
J
false
695750
D
232165
D
Restricted Stock Units
2023-10-11
4
A
false
695750
0.00
D
Common Stock
695750
0
D
Dr. Jennifer Buell was awarded Restricted Stock Units ("RSUs") which corresponded to 695,750 shares of MiNK Therapeutics, Inc. ("Company") common stock ("Common Stock"). These RSUs, tied to the Company's Initial Public Offering ("IPO"), vested on September 27, 2023. Dr. Buell previously reported on Form 4s the receipt of such shares of Common Stock (the "RSU Shares") and subsequent sales of shares of Common Stock to cover Federal, state and local tax withholding requirements. However, the Company and Dr. Buell agreed that it is in the best interests of the Company and its stockholders for Dr. Buell to forfeit that award in lieu of a new award that will vest over a period of five years (see Explanation of Responses #2). Therefore Dr. Buell is returning the RSU Shares to the Company. Dr Buell has thus made the Company whole for the forfeited award by returning 695,750 shares of Company Common Stock to the Company on October 11, 2023 for no consideration.
On October 11, 2023, in alignment with the Company's 2021 Equity Incentive Plan, Dr. Buell received a grant of 695,750 RSUs. This new grant serves as a replacement for the RSUs initially awarded during the Company's IPO, which Dr. Buell forfeited and returned to the Company on October 11, 2023. These newly granted RSUs will vest over a five-year period, with one-third of the restricted stock units vesting on each of the third, fourth and fifth anniversaries of the grant date.
By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. Buell
2023-10-13